From Nasdaq:

Innovent Biologics Inc. and Xuanzhu Biopharma have joined forces to explore combination therapies of sintilimab injection with KM-501 as possible treatment options for advanced solid tumors in China. Sintilimab, an innovative PD-1 inhibitor co-developed by Innovent and Eli Lilly and Company, has been approved for seven indications and is the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the national reimbursement drug list (NRDL). The Phase 1b clinical study will evaluate the anti-tumor activity and safety of this combination therapy in Chinese patients with advanced solid tumors. KM-501, a novel HER-2 bispecific ADC, is designed to target dual-antibody ADC with two different domains of HER2. It is suitable for the treatment of locally advanced/metastatic solid tumors with HER2 positive/expression, amplification, or mutation.



Read more: Innovent Biologics, Xuanzhu Collaborate On Clinical Trial For Advanced Solid Tumors In China